Genprex, Inc. (GNPX): Price and Financial Metrics

Genprex, Inc. (GNPX): $2.71

0.03 (-1.09%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add GNPX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#343 of 363

in industry

GNPX Price/Volume Stats

Current price $2.71 52-week high $46.00
Prev. close $2.74 52-week low $2.50
Day low $2.50 Volume 50,400
Day high $2.90 Avg. volume 83,026
50-day MA $5.40 Dividend yield N/A
200-day MA $15.31 Market Cap 4.03M

GNPX Stock Price Chart Interactive Chart >


Genprex, Inc. (GNPX) Company Bio


Genprex, Inc., a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome. The company was founded in 2009 and is based in Austin, Texas.


GNPX Latest News Stream


Event/Time News Detail
Loading, please wait...

GNPX Latest Social Stream


Loading social stream, please wait...

View Full GNPX Social Stream

Latest GNPX News From Around the Web

Below are the latest news stories about GENPREX INC that investors may wish to consider to help them evaluate GNPX as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning!

William White on InvestorPlace | November 30, 2023

Genprex Granted Orphan Drug Designation in Small Cell Lung Cancer

LOS ANGELES, CA - (NewMediaWire) - November 23, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Genprex was granted orphan drug designation by the FDA...

Yahoo | November 23, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

William White on InvestorPlace | November 17, 2023

Genprex to Present at BIO-Europe 2023

LOS ANGELES, CA - (NewMediaWire) - November 03, 2023 - (InvestorBrandNetwork via NewMediaWire) - IBN, a multifaceted financial news, content creation and publishing company, is utilized by both public and private companies to optimize investor awaren...

Yahoo | November 3, 2023

Genprex to Present at BIO-Europe 2023 Conference

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming BIO-Europe 2023 Conference taking place in Munich, Germany.

Yahoo | November 1, 2023

Read More 'GNPX' Stories Here

GNPX Price Returns

1-mo -35.48%
3-mo -70.54%
6-mo -82.84%
1-year -92.47%
3-year -98.40%
5-year -95.64%
YTD -70.54%
2023 -84.14%
2022 10.69%
2021 -68.43%
2020 1,196.88%
2019 -70.91%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!